🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 31 of 173

  1. US 11311624

    Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11311551

    Use of H3K9me3 modulation for enhancing cognitive function

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11311545

    Compositions and methods for the delivery of therapeutics

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11311526

    Radiation mitigator and method of use thereof

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11311541

    Treatment of GVHD

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11312787

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11312695

    Nutrients to enhance load-induced muscle hypertrophy

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11312714

    Compositions and methods for modulating hair growth

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11311507

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11305022

    Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11305002

    Compositions and treatments for Haemophilus influenzae

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11304911

    Compositions and methods for organ specific delivery of nucleic acids

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11304996

    Yeast-based immunotherapy and type I interferon sensitivity

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11306121

    Composition for muscle relaxation

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11306130

    PAR3 mimetic peptides and uses thereof

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11304916

    Methods and compositions for the treatment of Shiga Toxicosis

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11306287

    Method of generating skeletal muscle stem cells from pluripotent cells

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11298441

    Biodegradable biomimetics of growth plate cartilage for the treatment of physeal injuries

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11299520

    Compositions comprising a chimeric bacterial surface layer protein and methods of use thereof

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11298424

    Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11298309

    Topical silk compositions and methods of using

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11299512

    Cyclic di-nucleotide compounds and methods of use

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11299711

    Production of fully functional mature beta cells from human pancreatic progenitors

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11299515

    Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11292778

    Heterocyclyl polymethine IR chromophores

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11291707

    Polypeptide-polymer conjugates and methods of use thereof

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11293024

    Antisense antibacterial compounds and methods

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11293034

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11291653

    Compounds and methods for treating an epileptic disorder

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11291657

    Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11286279

    Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11285165

    Selective high-affinity polydentate ligands and methods of making such

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11285190

    CLEC11a is a bone growth agent

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11285182

    Reduction of milk glycans and their degradation products in the neonate gut

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11286463

    Reprogramming of aged adult stem cells

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11285100

    Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and/or compositions for therapeutic intra-articular injections

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11278626

    Compositions of polymeric nanowires and methods of making and using thereof

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11278573

    Methods and compositions to facilitate repair of avascular tissue

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11278592

    Methods and compositions for TUSC2 immunotherapy

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11279701

    Immunomodulators and immunomodulator conjugates

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11278554

    Compositions and methods for modification of biomolecules

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11279763

    Integrin alpha 9 blockade suppresses lymphatic valve formation and promotes transplant survival

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11274318

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11275080

    Methods for stratifying non-responders to therapies that block PD1/PDL1 axis

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11274294

    TAL effector-mediated DNA modification

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11274282

    Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11273431

    Biologically applicable water-soluble heterogeneous catalysts for para-hydrogen induced polarization

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11274130

    HV1 modulators and uses

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.